Why a COVID-19 trial is exciting BOD (ASX:BOD) investors today?

A clinical trial into the use of medicinal cannabis for long-term COVID-19 is going ahead.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The BOD Australia share price is up nearly 7%
  • The company's announced a new trial on treatment for long term COVID-19
  • It involves a medicinal cannabis product

The BOD Australia Ltd (ASX: BOD) share price is surging today amid news of a new COVID-19 clinical trial.

The company's shares are currently swapping hands at 23.5 cents, up 6.82%.

Let's take a look at what the company announced today?

Medicinal cannabis to treat COVID-19?

BOD investors are reacting to news of a clinical trial into the use of medicinal cannabis to treat long term COVID-19.

The company will work with Drug Science UK on the six-month trial featuring BOD's flagship product MediCabilis.

Symptoms of long term COVID-19 include chronic pain, anxiety, fatigue, and sleeping trouble. The trial will recruit 30 people suffering from the condition.

BOD is hopeful it will be able to commercialise its product in the UK and "other countries" if the trial is successful.

About 1.3 million people are estimated to have long-COVID-19 in the UK with 1 in 40 of these having symptoms lasting three months or more.

BOD said its MediCabilis product is already prescribed to treat people with long-COVID-19 symptoms including anxiety, sleep disorders, and chronic pain.

Management comment

Speaking on the news of the trial, CEO Jo Patterson said:

While there aren't any existing treatments for long-COVID, our medicinal cannabis products have been used to treat and alleviate a number of similar conditions.

We anticipate that this clinical trial will provide us with great insight into its potential to treat long-COVID and build on the body of evidence for the use of cannabis-based medicines, in place of other pharmaceuticals.

Share price snapshot

The BOD share price has crashed by 50% in the past year. Despite this, it is up 4% in the last month and nearly 7% in the past week.

In comparison, the S&P/ASX 200 Index (ASX: XJO) has returned more than 10% to investors in the past year.

The company commands a market capitalisation of about 24.9 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »